Psilocybin and Depression Study
PSILOCYBIN AND DEPRESSION STUDY
If you are between 19-65 years of age with mild-moderate Major Depressive Disorder (depression) and are currently taking selective-serotonin reuptake inhibitors (SSRIs), you may be eligible to participate in a study involving psilocybin-assisted therapy.
The purpose of this study is to evaluate whether the length of time someone has been taking SSRIs has an effect on their response to psilocybin-assisted therapy. The study drug, psilocybin, is naturally derived from certain types of mushrooms with psychoactive properties (magic mushrooms). In previous studies, psilocybin-assisted therapy demonstrated the potential to improve mood and anxiety, including depression.
All study-related care will be provided at no cost.
What the study will include
- Pre-screening phone interview
- Screening visit: to determine eligibility
- 3 pre-dose preparatory therapy sessions, a single psilocybin (25mg) dosing session, and 3 post-dose integration therapy sessions over 12 weeks
- Wearing a fitness tracking device for 1 month
- 5 assessment sessions including blood draws, questionnaires, and depression assessments
You may qualify as a study participant if:
- You are experiencing mild-moderate depressive symptoms
- You are on a stable dose of SSRIs (for at least 6 weeks)
- You have not used psychoactive substances (e.g., psilocybin, MDMA, LSD) in the last two months
The study requires you to participate in-person in Abbotsford, British Columbia.
More study information:
Site Principal Investigator (Study Doctor):